Skip to Main Content

Knowledge Center


The Monoclonal Antibody Revolution

What Insurers Need to Know

Hailed as a major scientific advance when they were introduced in the mid-1970s, monoclonal antibodies (mAbs) were slow to be applied outside of the lab. COVID-19 has changed everything.  

A rapid development of new and diverse medical indications for mAbs is underway. RGA's Dr. Daniel D. Zimmerman, Senior Vice President, Head of Global Medical, reviews the clinical indications of monoclonal antibodies, and examines the potential impact of this fast-growing class of therapeutics on insurance medicine. mAbs are also playing an emerging role in the treatment of COVID-19, and this will be addressed.

See also: The Monoclonal Antibody Revolution – What Insurers Need to Know 

At RGA, we are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to discuss and learn more about the RGA capabilities, resources, and solutions.  

The Presenter

  • Dr. Daniel D. Zimmerman
    Senior Vice President,
    Head of Global Medical

    Send email >


Curious about RGA's medical insights?  Contact us to learn more. 

This video was developed in conjunction with actuview, the first permanent international media platform for actuaries ( actuview content reflects contributions from actuarial institutions, corporate partners and industry professionals. RGA is actuview’s sponsoring partner.
  • actuarial pandemic
  • age covid
  • all-cause mortality covid
  • coronavirus
  • coronavirus pandemic